Outlook Therapeutics (NASDAQ:OTLK) released its earnings results on Wednesday. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.08, MarketWatch Earnings reports. The business had revenue of $0.64 million for the quarter.
Shares of Outlook Therapeutics stock opened at $1.53 on Friday. Outlook Therapeutics has a 52-week low of $0.85 and a 52-week high of $10.96.
Several research firms have weighed in on OTLK. ValuEngine cut Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, April 4th. Oppenheimer assumed coverage on Outlook Therapeutics in a report on Thursday. They set an “outperform” rating and a $12.00 price target for the company. CIBC assumed coverage on Outlook Therapeutics in a report on Thursday. They set an “outperform” rating and a $12.00 price target for the company. Finally, Ascendiant Capital Markets assumed coverage on Outlook Therapeutics in a report on Monday, April 22nd. They set a “buy” rating and a $4.00 price target for the company.
WARNING: This piece was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://dakotafinancialnews.com/2019/05/17/outlook-therapeutics-otlk-announces-quarterly-earnings-results.html.
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Story: Why Invest in Dividend Achievers?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.